ArticleMedical oncology (Northwood, London, England)2015
Short hairpin RNA (shRNA) of type 2 interleukin-1 receptor (IL1R2) inhibits the proliferation of human osteosarcoma U-2 OS cells.
Article in Medical oncology (Northwood, London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 17 citations in OpenAlex.
- IL-1R2 promotes tumorigenesis and modulates the tumor immune microenvironment in colorectal cancer.Cancer immunology, immunotherapy : CII · 2025Article
- Machine Learning-Driven Biomarker Discovery for Skeletal Complications in Type 1 Gaucher Disease Patients.International journal of molecular sciences · 2024Article
- IL1R2 is a Novel Prognostic Biomarker for Lung Adenocarcinoma.Current molecular medicine · 2024Article
- Article
- The Therapeutic Prospects of Targeting IL-1R1 for the Modulation of Neuroinflammation in Central Nervous System Disorders.International journal of molecular sciences · 2022Review
- IL1R2 Blockade Suppresses Breast Tumorigenesis and Progression by Impairing USP15-Dependent BMI1 Stability.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020Article
- Immunosignature Screening for Multiple Cancer Subtypes Based on Expression Rule.Frontiers in bioengineering and biotechnology · 2019Article
- Differential transcriptional changes in human alveolar epithelial A549 cells exposed to airborne PMEnvironmental science and pollution research international · 2018Article
- Expression of concern: Short hairpin RNA (shRNA) of type 2 interleukin-1 receptor (IL1R2) inhibits the proliferation of human osteosarcoma U-2 OS cells.Medical oncology (Northwood, London, England) · 2018Article
- miR-486 suppresses the development of osteosarcoma by regulating PKC-δ pathway.International journal of oncology · 2017Article
- Microarray expression profiling identifies genes, including cytokines, and biofunctions, as diapedesis, associated with a brain metastasis from a papillary thyroid carcinoma.American journal of cancer research · 2016Article
Corrections and comments
- Expression of concern · 2018-08-17Author Unresponsive · Concerns/Issues about Data · Concerns/Issues about Referencing/Attributions ·
- Expression of concern
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 2 interleukin-1 receptor (IL1R2) is a member of the IL1 family. It has been reported that IL1R2 is expressed and plays important roles in several cancers. However, its potential role in human osteosarcoma has not been reported. In the present study, a recombinant lentivirus harboring short hairpin RNA against IL1R2 was constructed and then transfected human osteosarcoma U-2 OS cells. The proliferation of infected cells was measured by 3-(4, 5- dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) assay and plate colony formation assay. Results showed that efficiency of lentivirus infection was more than 80 %. The knockdown efficiency of IL1R2 mRNA level was up to 95 % compared with control group. After treatment with lentiviruses containing shIL1R2 (Lv-shIL1R2), the proliferation and colony formation of U-2 OS cells were obviously reduced (P < 0.001). Cell cycle assay was used to investigate the mechanism of the inhibition of proliferation of U-2 OS cells. We found that after Lv-shIL1R2 treatment, the percentage of cells at G0/G1 phase decreased significantly, whereas cells at S and G2/M phases increased markedly (P < 0.05). In conclusion, shIL1R2 indeed inhibited the proliferation of U-2 OS cells which might be associated with the blockage of S and G2/M phases. The results suggested that IL1R2 could have oncogenic potential and shIL1R2 might represent a new and effective therapeutic treatment for osteosarcoma patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.